store at low temperature
store at -20°C
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members.Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis and psoriasis. arthritis, and psoriasis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 136.00 | |
5 mg | In stock | $ 462.00 | |
10 mg | In stock | $ 678.00 | |
25 mg | In stock | $ 1,070.00 | |
50 mg | In stock | $ 1,430.00 |
Description | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members.Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis and psoriasis. arthritis, and psoriasis. |
In vitro |
Ixekizumab (0.1-10000 pM) dose-dependently inhibits the secretion of growth-regulated oncogene (GRO)α induced by human IL-17A or human IL-17A/F heterodimers from HT-29 cells. Similarly, Ixekizumab demonstrates dose-dependent inhibition of GROα secretion from HT-29 cells induced by cynomolgus monkey IL-17A.[1] The equilibrium KD values of Ixekizumab for IL-17A in humans and cynomolgus monkeys were 1.8 pM and 0.8 pM, respectively. Ixekizumab exhibited binding to rabbit IL-17A as well, although with a lower affinity and heterogeneous binding (with KD values of 1.3 nM and 14 nM, respectively). Notably, Ixekizumab did not demonstrate any binding to IL-17A in either mice or rats.[1] |
In vivo |
Ixekizumab (0.001-1 mg/kg; i.v.; C57BL/6 mice) exhibits a dose-dependent reduction in the secretion of keratinocyte chemoattractant (KC) induced by human IL-17A in the plasma of C57BL/6 mice. In male cynomolgus monkeys, upon intravenous (IV) administration of 1 mg/kg, Ixekizumab exhibits a mean half-life of 6.5 days for elimination. Subcutaneous (SC) administration of 1 mg/kg leads to an average maximum plasma concentration of approximately 11.1 µg/mL around 72 hours after dosing. The mean elimination half-life following the SC injection was approximately 10.3 days.[1] |
Synonyms | LY2439821 |
Molecular Weight | N/A |
Formula | N/A |
CAS No. | 1143503-69-8 |
store at low temperature
store at -20°C
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ixekizumab 1143503-69-8 Immunology/Inflammation Interleukin IL Receptor LY 2439821 LY-2439821 LY2439821 inhibitor inhibit